Click on the subcategory below to find drug monographs for that particular area.
Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Download or print easy-to-read disease leaflets for your patients.
Among men with very-low-risk prostate cancer who meet criteria for active surveillance but undergo radical prostatectomy, African-American race is associated with poorer outcomes, with higher rates of disease upgrading and adverse pathology.
Gilead Sciences announced interim results from its Phase 2 Study 101-09 evaluating idelalisib, an oral PI3K delta inhibitor for the treatment of patients with indolent non-Hodgkin's lymphoma that is refractory to rituximab and to alkylating-agent containing chemotherapy. If approved it may provide a new treatment option to patients with few remaining conventional treatment options.
Pharmacyclics and Janssen R&D announced results from their Phase 2 MCL and DLBCL study stating that ibrutinib, an investigational BTK inhibitor, demonstrated efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse B-cell lymphoma (DLBCL).
Outcomes are similar between men with histologically comparable prostate cancer who receive a radical prostatectomy after a period of active surveillance and those with low-risk disease who undergo immediate prostatectomy.
Obesity is associated with significantly increased risks for incidence of colorectal adenoma and colorectal cancer in middle-aged and older men who are screened with sigmoidoscopy.
Nurses need to know how to assess a patient’s risk of TLS and the treatment goals for successful management.0.75 CE for Nurses
The integration of billing procedures into medical records introduces the need for nurses to understand billing systems and medical payors.0.75 CE for Nurses
The issue of cancer care disparity is complex, as it is both a medical and a socioeconomic issue. Socioeconomic factors are the most universal contributors.0.50 CE for Nurses